Movatterモバイル変換


[0]ホーム

URL:


IL266596A - Agents, uses and methods for the treatment of synucleinopathy - Google Patents

Agents, uses and methods for the treatment of synucleinopathy

Info

Publication number
IL266596A
IL266596AIL266596AIL26659619AIL266596AIL 266596 AIL266596 AIL 266596AIL 266596 AIL266596 AIL 266596AIL 26659619 AIL26659619 AIL 26659619AIL 266596 AIL266596 AIL 266596A
Authority
IL
Israel
Prior art keywords
synucleinopathy
agents
treatment
methods
Prior art date
Application number
IL266596A
Other languages
Hebrew (he)
Inventor
Pekka Kallunki
Paul EG KRISTJANSEN
Original Assignee
H Lundbeck As
Pekka Kallunki
Paul EG KRISTJANSEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As, Pekka Kallunki, Paul EG KRISTJANSENfiledCriticalH Lundbeck As
Publication of IL266596ApublicationCriticalpatent/IL266596A/en

Links

Classifications

Landscapes

IL266596A2016-11-152019-05-13Agents, uses and methods for the treatment of synucleinopathyIL266596A (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
DKPA2016007102016-11-15
PCT/EP2017/079153WO2018091444A1 (en)2016-11-152017-11-14Agents, uses and methods for the treatment of synucleinopathy

Publications (1)

Publication NumberPublication Date
IL266596Atrue IL266596A (en)2019-07-31

Family

ID=62145269

Family Applications (1)

Application NumberTitlePriority DateFiling Date
IL266596AIL266596A (en)2016-11-152019-05-13Agents, uses and methods for the treatment of synucleinopathy

Country Status (16)

CountryLink
US (2)US10889635B2 (en)
EP (1)EP3541836A1 (en)
JP (1)JP7217229B2 (en)
KR (1)KR102593669B1 (en)
CN (1)CN109937210B (en)
AR (1)AR110074A1 (en)
AU (1)AU2017359944B2 (en)
BR (1)BR112018014281A2 (en)
CA (1)CA3043651A1 (en)
CL (2)CL2019001293A1 (en)
CO (1)CO2019004755A2 (en)
IL (1)IL266596A (en)
MA (1)MA46836A (en)
MX (1)MX2019005594A (en)
RU (1)RU2019114679A (en)
WO (1)WO2018091444A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB201512203D0 (en)2015-07-132015-08-19Lundbeck & Co As HAgents,uses and methods
CN109937210B (en)*2016-11-152023-09-15H.隆德贝克有限公司 Agents, uses and methods for treating synucleinopathies
BR112018016717A2 (en)2016-12-162018-12-26H Lundbeck As agents, uses and methods
US10364286B2 (en)2016-12-222019-07-30H. Lundbeck A/SMonoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN110506057B (en)2017-02-172023-09-29百时美施贵宝公司ALPHA synuclein antibody and application thereof
GB201720970D0 (en)2017-12-152018-01-31Ucb Biopharma SprlAntibodies
GB201720975D0 (en)2017-12-152018-01-31Ucb Biopharma SprlAnti-alpha synuclein antibodies
TWI734279B (en)*2018-12-142021-07-21美商美國禮來大藥廠Anti-alpha-synuclein antibodies and uses thereof
WO2020212593A1 (en)*2019-04-182020-10-22Ac Immune SaNovel molecules for therapy and diagnosis
AU2020262416A1 (en)*2019-04-242021-12-16Regenxbio Inc.Fully-human post-translationally modified antibody therapeutics
CN111671757A (en)*2020-07-162020-09-18福建医科大学附属协和医院 3-[4-(4-Morpholinyl)-7H-pyrrolo[2,3-D]pyrimidin-5-yl]benzonitrile Pharmaceutical Uses
JP2023535024A (en)2020-07-232023-08-15オター プロシーナ リミテッド anti-Abeta antibody
US20220315651A1 (en)*2021-03-082022-10-06Prothena Biosciences LimitedTreatment of Parkinson's Disease
KR102701076B1 (en)*2021-08-032024-09-03아주대학교산학협력단Composition for treating or diagnosing osteoarthritis targeting SNCG
JP2024534947A (en)2021-09-162024-09-26ハー・ルンドベック・アクチエゼルスカベット Compositions and methods for treating synucleinopathies
AU2023316021A1 (en)2022-07-292025-03-06Alector LlcCd98hc antigen-binding domains and uses therefor
WO2024026472A2 (en)2022-07-292024-02-01Alector LlcTransferrin receptor antigen-binding domains and uses therefor
WO2024242530A1 (en)*2023-05-192024-11-28Yunovia Co., Ltd.Compound for neuroprotection, or treating diseases related to alpha-synuclein and/or neuro-inflammation
US12102693B1 (en)2023-08-252024-10-01Nanomedtrix, LlcPharmaceutical composition with nanoparticle-based drug delivery combined with non-invasive radiographic monitoring model

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4179337A (en)1973-07-201979-12-18Davis Frank FNon-immunogenic polypeptides
JPS5896026A (en)1981-10-301983-06-07Nippon Chemiphar Co LtdNovel urokinase derivative, its preparation and thrombolytic agent containing the same
EP0098110B1 (en)1982-06-241989-10-18NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTDLong-acting composition
US4766106A (en)1985-06-261988-08-23Cetus CorporationSolubilization of proteins for pharmaceutical compositions using polymer conjugation
US5225539A (en)1986-03-271993-07-06Medical Research CouncilRecombinant altered antibodies and methods of making altered antibodies
US4946778A (en)1987-09-211990-08-07Genex CorporationSingle polypeptide chain binding molecules
US5750172A (en)1987-06-231998-05-12Pharming B.V.Transgenic non human mammal milk
GB8823869D0 (en)1988-10-121988-11-16Medical Res CouncilProduction of antibodies
US5530101A (en)1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
US5633076A (en)1989-12-011997-05-27Pharming BvMethod of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en)1989-12-211999-01-12Celltech LimitedHumanised antibodies
US6300129B1 (en)1990-08-292001-10-09Genpharm InternationalTransgenic non-human animals for producing heterologous antibodies
AU8507191A (en)1990-08-291992-03-30Genpharm International, Inc.Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)1990-08-291996-08-13Genpharm International, Inc.Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)1990-08-291997-08-26Genpharm International Inc.Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en)1990-08-291998-09-29Genpharm International Inc.Transgenic non-human animals for producing heterologous antibodies
US5877397A (en)1990-08-291999-03-02Genpharm International Inc.Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en)1990-08-291997-04-29Genpharm International, Inc.Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)1990-08-291997-05-27Genpharm International, Inc.Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en)1990-08-291999-02-23Genpharm International, Inc.Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)1990-08-291998-06-23Genpharm International, Inc.Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)1990-08-291998-08-04Genpharm International, Inc.Transgenic non-human animals for producing heterologous antibodies
WO1992022645A1 (en)1991-06-141992-12-23Genpharm International, Inc.Transgenic immunodeficient non-human animals
WO1992022653A1 (en)1991-06-141992-12-23Genentech, Inc.Method for making humanized antibodies
JPH06508880A (en)1991-07-081994-10-06ユニバーシティ オブ マサチューセッツ アット アムハースト Thermotropic liquid crystal segmented block copolymer
JP3801196B2 (en)1993-03-092006-07-26ジェンザイム・コーポレイション Isolation of the target compound from milk
EP0754225A4 (en)1993-04-262001-01-31Genpharm IntTransgenic non-human animals capable of producing heterologous antibodies
US5827690A (en)1993-12-201998-10-27Genzyme Transgenics CorporatiionTransgenic production of antibodies in milk
DE60037896D1 (en)1999-07-292008-03-13Medarex Inc HUMAN ANTIBODIES AGAINST HER2 / NEU
JP4093757B2 (en)1999-08-242008-06-04メダレックス, インコーポレイテッド Human CTLA-4 antibody and use thereof
CA2415179A1 (en)2000-07-072002-01-17Panacea Pharmaceuticals, Inc.Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
PT1354034E (en)2000-11-302008-02-28Medarex IncTransgenic transchromosomal rodents for making human antibodies
WO2003000714A2 (en)2001-06-222003-01-03Panacea Pharmaceuticals, Inc.Compositions and methods for preventing protein aggregation in neurodegenerative diseases
EP1539233B1 (en)2001-07-122011-04-27FOOTE, JeffersonSuper humanized antibodies
US8829198B2 (en)2007-10-312014-09-09Proteotech IncCompounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
TW200509968A (en)2002-11-012005-03-16Elan Pharm IncPrevention and treatment of synucleinopathic disease
US20080014194A1 (en)2003-10-312008-01-17Elan Pharmaceuticals, Inc.Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en)2002-11-012013-08-13Neotope Biosciences LimitedPrevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en)*2003-10-312015-05-19Prothena Biosciences LimitedTreatment and delay of outset of synucleinopathic and amyloidogenic disease
US7358331B2 (en)2003-05-192008-04-15Elan Pharmaceuticals, Inc.Truncated fragments of alpha-synuclein in Lewy body disease
HUE035044T2 (en)2003-05-192018-05-02Prothena Biosciences LtdTruncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (en)*2003-11-082005-05-26Elan Pharmaceuticals, Inc.Antibodies to alpha-synuclein
JP2006031250A (en)2004-07-142006-02-02Fuji Xerox Co LtdCommunication equipment and its control method
MX2007001679A (en)2004-08-092007-05-23Elan Pharm IncPrevention and treatment of synucleinopathic and amyloidogenic disease.
ZA200701531B (en)*2004-08-092009-03-25Elan Pharm IncPrevention and treatment of synucleinopathic and amyloidogenic disease
US20060205024A1 (en)2005-03-082006-09-14Sun Health Research InstituteMethod to diagnose and evaluate progression of Alzheimer's disease
CA2657953A1 (en)2005-07-192007-01-25University Of RochesterAlpha-synuclein antibodies and methods related thereto
CA2631184A1 (en)2005-11-282007-05-31Genmab A/SRecombinant monovalent antibodies and methods for production thereof
ES2727407T3 (en)2007-02-232019-10-16Prothena Biosciences Ltd Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2118300B1 (en)2007-02-232015-05-27Prothena Biosciences LimitedPrevention and treatment of synucleinopathic and amyloidogenic disease
WO2009097006A2 (en)2007-08-102009-08-06Medarex, Inc.Hco32 and hco27 and related examples
WO2009133521A2 (en)2008-04-292009-11-05Bioartic Neuroscience AbAntibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
NZ595630A (en)*2009-04-092013-04-26Amicus Therapeutics IncMethods for preventing and/or treating degenerative disorders of the central nervous system
HUE038313T2 (en)*2010-02-262018-10-29Bioarctic Neuroscience AbProtofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
EP2366714A1 (en)2010-03-032011-09-21Dr. Rentschler Holding GmbH & Co. KGNaturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
GB201008682D0 (en)2010-05-252010-07-07Vib VzwEpitope tag for affinity based applications
KR101308898B1 (en)*2011-02-082013-09-23건국대학교 산학협력단A NOVEL ANTI-α-CYNUCLEIN MONOCLONAL ANTIBADY AND ELISA SYSTEM USING THE SAME
ES2699801T3 (en)*2011-06-232019-02-12Biogen Int Neuroscience Gmbh Anti-alpha synuclein binding molecules
JP2013059866A (en)2011-09-122013-04-04Seiko Epson CorpLiquid ejecting apparatus, method of controlling liquid ejecting apparatus, and program for controlling liquid ejecting apparatus
HUE037811T2 (en)2011-10-282018-09-28Prothena Biosciences LtdHumanized antibodies that recognize alpha-synuclein
CN104781278B (en)2012-07-032018-06-12华盛顿大学For the antibody of TAU
UA118441C2 (en)2012-10-082019-01-25Протена Біосаєнсиз ЛімітедAntibodies recognizing alpha-synuclein
CN104869993B (en)*2012-10-252019-01-15通用医疗公司The combination treatment for treating Alzheimer disease and related disease
US9534044B2 (en)2013-02-282017-01-03United Arab Emirates UniversityAlpha-synuclein antibodies and uses thereof
US10513555B2 (en)2013-07-042019-12-24Prothena Biosciences LimitedAntibody formulations and methods
RS60882B1 (en)2013-11-212020-11-30Hoffmann La RocheAnti-alpha-synuclein antibodies and methods of use
US9732148B2 (en)*2014-10-162017-08-15Genentech, Inc.Anti-α-synuclein antibodies and methods of use
MX381333B (en)*2014-12-222025-03-12Tetra Laval Holdings & Finance PACKAGING MATERIAL AND PACKAGING CONTAINER FORMED FROM THE MATERIAL.
CN107949386A (en)*2015-05-072018-04-20阿速万科学有限责任公司 Compositions and methods for treating neurodegenerative diseases
GB201512203D0 (en)*2015-07-132015-08-19Lundbeck & Co As HAgents,uses and methods
JP7628764B2 (en)*2015-09-292025-02-12アムジエン・インコーポレーテツド mod folkpon edge cargogo search carrier Signalsure procedure always Subaturch curl carrieresert match experiencesch suffer with Japan missed crgoc car
SMT202200008T1 (en)2016-06-022022-03-21Medimmune LtdAntibodies to alpha-synuclein and uses thereof
CN109937210B (en)*2016-11-152023-09-15H.隆德贝克有限公司 Agents, uses and methods for treating synucleinopathies
BR112018016717A2 (en)2016-12-162018-12-26H Lundbeck As agents, uses and methods
US10364286B2 (en)2016-12-222019-07-30H. Lundbeck A/SMonoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
US20230074436A1 (en)*2019-09-202023-03-09Denali Therapeutics Inc.Anti-alpha-synuclein antibodies and methods of use thereof
JP2024534947A (en)*2021-09-162024-09-26ハー・ルンドベック・アクチエゼルスカベット Compositions and methods for treating synucleinopathies

Also Published As

Publication numberPublication date
AU2017359944A1 (en)2019-05-23
JP2020500849A (en)2020-01-16
KR20190083356A (en)2019-07-11
US20180194833A1 (en)2018-07-12
CN109937210B (en)2023-09-15
US20210236634A1 (en)2021-08-05
RU2019114679A3 (en)2021-03-30
WO2018091444A1 (en)2018-05-24
AU2017359944B2 (en)2024-07-18
US10889635B2 (en)2021-01-12
KR102593669B1 (en)2023-10-25
AR110074A1 (en)2019-02-20
JP7217229B2 (en)2023-02-02
RU2019114679A (en)2020-12-17
CL2021003306A1 (en)2022-07-22
EP3541836A1 (en)2019-09-25
BR112018014281A2 (en)2018-12-18
CO2019004755A2 (en)2019-05-21
CL2019001293A1 (en)2019-07-19
CA3043651A1 (en)2018-05-24
CN109937210A (en)2019-06-25
MX2019005594A (en)2019-07-04
MA46836A (en)2019-09-25

Similar Documents

PublicationPublication DateTitle
IL266596A (en)Agents, uses and methods for the treatment of synucleinopathy
IL256501B (en)Agents, uses and methods for the treatment of synucleinopathy
IL264049A (en)Compounds, compositions, and methods for the treatment of disease
IL275482A (en)Esketamine for the treatment of depression
IL279627A (en)Method for the treatment of depression
IL258002A (en)Cenicriviroc combination therapy for the treatment of fibrosis
IL264156A (en)Compounds, compositions, and methods for the treatment of disease
IL269371A (en)Treatment methods
EP3151797A4 (en)Methods and devices for treating the skin
PL3286311T3 (en)Method for the treatment of malignancies
GB2588261B (en)Apparatus, use of the apparatus and arrangement
GB201608885D0 (en)Treatment
IL271728A (en)Agents, uses and methods for treatment
GB201512215D0 (en)Agents,uses and methods
EP3173089A4 (en)Brain function improving agent, and prophylactic or therapeutic agent for cognitive dysfunction
IL256350A (en)Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
IL252197A0 (en)Method for treating, preventing, or reducing the risk of skin infection
IL258137A (en)Means for the treatment of hiv
IL253617A0 (en)Cenicriviroc for the treatment of fibrosis
DK3313207T3 (en)Compositions and methods for the treatment of malnutrition
EP3302684A4 (en)Methods and devices for treating the cornea
PL3292226T3 (en)Method for the treatment of iron-containing sludge
IL269681A (en)New methods for the treatment of multiple sclerosis
HK40013476A (en)Agents, uses and methods for the treatment of synucleinopathy
GB201701936D0 (en)New methods for the treatment of hyperglycaemia

[8]ページ先頭

©2009-2025 Movatter.jp